Eli Lilly and Co. stock: Goldman lifts target to USD 1,413, falls pre-market
Published on 10/21/2026 at 08:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst action and earnings date
- Goldman Sachs raised its Eli Lilly target to USD 1,413.00 on October 20, 2026.
- Lilly's third-quarter 2026 earnings call is scheduled for October 29, 2026.
- Eli Lilly and Co. stock trades pre-market at EUR 1,137.70 at 8:26 a.m. CEST at Lang & Schwarz on October 21, 2026, 1.50 percent below the Xetra close of October 20, 2026.
Goldman Sachs raised its price target for Eli Lilly and Co. to USD 1,413.00 and reiterated a Buy rating on October 20, 2026, according to MarketBeat. Eli Lilly and Co. stock trades pre-market at EUR 1,137.70 at 8:26 a.m. CEST at Lang & Schwarz on October 21, 2026, 1.50 percent below the Xetra close of October 20, 2026 (EUR 1,155.00).
Goldman Sachs raises target
MarketBeat said Goldman Sachs increased the target from USD 1,371.00 to USD 1,413.00 while maintaining its Buy rating. The report linked the analyst view to expectations for third-quarter earnings strength and continued growth in Lilly's Mounjaro and Zepbound franchises. The analyst action was dated October 20, 2026.
Ahead of the Xetra open
The pre-market indication is EUR 17.30 below the reference level. The bid is EUR 1,135.60 and the ask is EUR 1,139.80. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Eli Lilly stock.
The group and its market
Eli Lilly discovers, develops, manufactures and markets medicines across areas including diabetes, obesity, oncology, immunology, neuroscience and cardiovascular health. The company's investor-relations site schedules its third-quarter 2026 earnings call for October 29, 2026 at 10:00 a.m. EDT. Eli Lilly and Company lists the event among its upcoming investor events.
Market context: Market report S&P 500.
